ES2414872T3 - Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente - Google Patents

Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente Download PDF

Info

Publication number
ES2414872T3
ES2414872T3 ES05767978T ES05767978T ES2414872T3 ES 2414872 T3 ES2414872 T3 ES 2414872T3 ES 05767978 T ES05767978 T ES 05767978T ES 05767978 T ES05767978 T ES 05767978T ES 2414872 T3 ES2414872 T3 ES 2414872T3
Authority
ES
Spain
Prior art keywords
app
antibodies
plasma
amyloid
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05767978T
Other languages
English (en)
Spanish (es)
Other versions
ES2414872T8 (es
Inventor
Franck Mattner
Walter Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris Forschungs und Entwicklungs GmbH
Affiris AG
Original Assignee
Affiris Forschungs und Entwicklungs GmbH
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Forschungs und Entwicklungs GmbH, Affiris AG filed Critical Affiris Forschungs und Entwicklungs GmbH
Application granted granted Critical
Publication of ES2414872T3 publication Critical patent/ES2414872T3/es
Publication of ES2414872T8 publication Critical patent/ES2414872T8/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
ES05767978T 2004-07-13 2005-07-06 Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente Expired - Lifetime ES2414872T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT11852004 2004-07-13
AT0118504A AT500483B1 (de) 2004-07-13 2004-07-13 Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
PCT/EP2005/053224 WO2006005706A2 (de) 2004-07-13 2005-07-06 Kombinationstherapie zur vorbeugung oder behandlung der alzheimer´schen erkrankung sowie kit hierfür

Publications (2)

Publication Number Publication Date
ES2414872T3 true ES2414872T3 (es) 2013-07-23
ES2414872T8 ES2414872T8 (es) 2014-11-06

Family

ID=35115768

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05767978T Expired - Lifetime ES2414872T3 (es) 2004-07-13 2005-07-06 Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente

Country Status (14)

Country Link
US (2) US7935348B2 (enExample)
EP (1) EP1765388B8 (enExample)
JP (2) JP5642333B2 (enExample)
KR (1) KR101158600B1 (enExample)
CN (1) CN101022825B (enExample)
AT (1) AT500483B1 (enExample)
AU (1) AU2005261687B8 (enExample)
CA (1) CA2577332C (enExample)
DK (1) DK1765388T3 (enExample)
ES (1) ES2414872T3 (enExample)
PL (1) PL1765388T3 (enExample)
PT (1) PT1765388E (enExample)
TW (1) TW200602072A (enExample)
WO (1) WO2006005706A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
CA2628703C (en) * 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
RU2009128039A (ru) * 2006-12-22 2011-01-27 Дженентек, Инк. (Us) Антагонисты dr6 и способы их применения в лечении неврологических нарушений
WO2008104386A2 (en) * 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2226081A4 (en) * 2007-10-25 2011-10-12 Univ Kagoshima PEPTIDE VACCINE WITH A MIMIC MOLECULE OF AMYLOID PEPTIDE
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
EP2320987A1 (en) * 2008-07-29 2011-05-18 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
DK2365804T3 (en) * 2008-11-13 2015-07-27 Modgene Llc The reduction of amyloid-beta burden in tissues that are not derived from brain
CN104274875A (zh) 2008-12-22 2015-01-14 学校法人藤田学园 Aβ 除去材料、Aβ 除去器和Aβ 除去系统
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
JP5843345B2 (ja) 2010-07-08 2016-01-13 旭化成メディカル株式会社 β−アミロイド除去システム
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
ES2496341T3 (es) 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
CA2853961C (en) 2011-11-01 2016-09-20 Modgene, Llc Compositions and methods for reduction of amyloid-beta load
IN2014MN02060A (enExample) * 2012-03-18 2015-08-21 Univ Kyushu Nat Univ Corp
DK2834643T3 (da) 2012-04-05 2020-02-03 Forschungszentrum Juelich Gmbh Fremgangsmåde til behandling af blod, blodprodukter og organer
CN104380111B (zh) 2012-04-05 2017-08-29 于利希研究中心有限公司 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
ES2757595T3 (es) * 2014-03-11 2020-04-29 Jacques Fantini Un péptido quimérico que interactúa con los gangliósidos de la membrana celular
CN106466298A (zh) * 2015-08-14 2017-03-01 上海交通大学医学院 一种单唾液酸四己糖神经节苷脂修饰的重组脂蛋白及其应用
WO2017197253A2 (en) * 2016-05-12 2017-11-16 Ohio State Innovation Foundation Peptides and methods for treating neurodegenerative disorders
AU2018304194B2 (en) * 2017-07-17 2025-02-27 Spark Therapeutics, Inc. Apheresis methods and uses
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
CN115957324A (zh) * 2021-10-12 2023-04-14 首都医科大学宣武医院 外周CLU作为靶点在降低脑Aβ中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476715A (en) 1989-10-03 1995-12-19 Fresenius Ag Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
AU691297B2 (en) 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
EP0886085B1 (en) 1997-06-18 2002-04-03 Morse Tec Europe S.p.A. Sprocket wheel with improved tooth profile for greater silentness
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP2002533169A (ja) 1998-12-29 2002-10-08 オキュロジックス コーポレイション レオロジー的処置方法および関連するアフェレーシスシステム
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE60217107T2 (de) 2001-06-20 2007-08-23 Ramot At Tel Aviv University Ltd. Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
WO2003051374A2 (en) 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
AU2003250102B2 (en) * 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Also Published As

Publication number Publication date
AT500483B1 (de) 2006-01-15
US20110201987A1 (en) 2011-08-18
WO2006005706A2 (de) 2006-01-19
CN101022825B (zh) 2015-02-04
AU2005261687B2 (en) 2011-02-17
HK1103354A1 (en) 2007-12-21
PL1765388T3 (pl) 2013-09-30
EP1765388B8 (de) 2013-05-29
CN101022825A (zh) 2007-08-22
JP5642333B2 (ja) 2014-12-17
WO2006005706A8 (de) 2006-11-16
EP1765388B1 (de) 2013-04-17
ES2414872T8 (es) 2014-11-06
US7935348B2 (en) 2011-05-03
US20080051690A1 (en) 2008-02-28
AU2005261687B8 (en) 2011-07-21
DK1765388T3 (da) 2013-07-22
KR101158600B1 (ko) 2012-07-09
EP1765388A2 (de) 2007-03-28
AT500483A4 (de) 2006-01-15
JP2013116903A (ja) 2013-06-13
PT1765388E (pt) 2013-05-24
CA2577332A1 (en) 2006-01-19
TWI350173B (enExample) 2011-10-11
KR20070036158A (ko) 2007-04-02
TW200602072A (en) 2006-01-16
WO2006005706A3 (de) 2006-07-20
CA2577332C (en) 2014-12-09
JP2008506665A (ja) 2008-03-06
AU2005261687A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
ES2414872T3 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
Winblad et al. Active immunotherapy options for Alzheimer’s disease
Rosenmann Immunotherapy for targeting tau pathology in Alzheimer’s disease and tauopathies
US9289488B2 (en) Vaccine engineering
JP2008506665A5 (enExample)
US20230257433A1 (en) Heterologous Administration of Tau Vaccines
ES2298789T3 (es) Dispositivo de aferesis.
US9770496B2 (en) Method for treating amyloid disease
Wang et al. Immunotherapy for Alzheimer's disease
HK1103354B (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
Triplett et al. Active immunization targeting amyloid β for the treatment of Alzheimer’s disease
Winblad et al. Active immunotherapy options for Alzheimer’s